Hazlett, Burt & Watson’s GSK GSK Stock Holding History

Hazlett, Burt & Watson’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-766	Closed	-$30K	–	815
2025 Q1	$30K	Sell	766 -760	-50%	-$27.8K	0.01%	433
2024 Q4	$52K	Buy	1,526 +1	+0.1%	+$36	0.02%	359
2024 Q3	$63K	Buy	1,525 +1	+0.1%	+$41	0.03%	327
2024 Q2	$58K	Buy	1,524 +1	+0.1%	+$42	0.03%	318
2024 Q1	$65K	Buy	1,523 +1	+0.1%	+$41	0.04%	297
2023 Q4	$56K	Buy	1,522 +1	+0.1%	+$36	0.04%	290
2023 Q3	$56K	Buy	1,521 +100	+7%	+$3.55K	0.04%	282
2023 Q2	$51K	Buy	1,421 +111	+8%	+$3.98K	0.04%	295
2023 Q1	$46K	Buy	1,310 +650	+98%	+$22.7K	0.04%	289
2022 Q4	$23K	Sell	660 -520	-44%	-$17.3K	0.02%	364
2022 Q3	$34K	Hold	1,180	–	–	0.03%	304
2022 Q2	$64K	Hold	1,180	–	–	0.06%	244
2022 Q1	$64K	Buy	+1,180	New	+$64.1K	0.05%	253

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Hazlett, Burt & Watson's GSK Position: Q2 2025 in Review

Hazlett, Burt & Watson sold out of GSK (GSK) in Q2 2025, closing a stake of 766 shares — an estimated $30K sold.

Hazlett, Burt & Watson first reported a position in GSK in Q1 2022 and held it in 13 quarters. The position peaked at $65K in Q1 2024. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

Hazlett, Burt & Watson reported no remaining GSK position as of Q2 2025 after selling out during the quarter.
Hazlett, Burt & Watson sold 766 GSK shares in Q2 2025, an estimated $30K.
Hazlett, Burt & Watson first reported a position in GSK in Q1 2022 and held it in 13 quarters.
Hazlett, Burt & Watson's GSK position peaked at $65K in Q1 2024.
890 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2025, filed 25 Jul 2025.